Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to -$14.8 million.

  • Arrowhead Pharmaceuticals' Cash from Financing Activities fell 17148.4% to -$14.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $38.6 million, marking a year-over-year decrease of 9566.48%. This contributed to the annual value of $74.0 million for FY2025, which is 9149.86% down from last year.
  • According to the latest figures from Q4 2025, Arrowhead Pharmaceuticals' Cash from Financing Activities is -$14.8 million, which was down 17148.4% from $3.7 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Cash from Financing Activities ranged from a high of $430.8 million in Q1 2024 and a low of -$42.7 million during Q2 2025
  • In the last 5 years, Arrowhead Pharmaceuticals' Cash from Financing Activities had a median value of $2.3 million in 2021 and averaged $62.7 million.
  • Per our database at Business Quant, Arrowhead Pharmaceuticals' Cash from Financing Activities surged by 8274173.08% in 2024 and then plummeted by 18470.24% in 2025.
  • Arrowhead Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $1.9 million in 2021, then surged by 13193.16% to $250.6 million in 2022, then plummeted by 99.89% to $267000.0 in 2023, then surged by 7628.09% to $20.6 million in 2024, then tumbled by 171.48% to -$14.8 million in 2025.
  • Its Cash from Financing Activities was -$14.8 million in Q4 2025, compared to $3.7 million in Q3 2025 and -$42.7 million in Q2 2025.